NCT05808049View on ClinicalTrials.gov

A Clinical Trial to Evaluate the Efficacy and Safety of MXP22 on Liver Health

NACompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

October 6, 2022

Primary Completion Date

July 4, 2023

Study Completion Date

July 4, 2023

Conditions
Non-Alcoholic Fatty Liver Disease
Interventions
OTHER

MXP22 (Probiotic and antioxidant capsule)

Dose: NLT 4 Billion CFU/Capsule Route: Oral Administration Regimen: 1 capsule to be taken once daily after lunch for 120 days

OTHER

Placebo (Microcrystalline Cellulose)

Dose: NLT 4 Billion CFU/Capsule Route: Oral Administration Regimen: 1 capsule to be taken once daily after lunch for 120 days

Trial Locations (2)

302001

Dr. Sudhir Maharshi Gastro clinic, Jaipur

302017

JNU institute of medical science and research, Jaipur

All Listed Sponsors
lead

Vedic Lifesciences Pvt. Ltd.

INDUSTRY